Selected article for: "lung cancer and non small lung cancer"
Author: Kaul, Karen L.; Sabatini, Linda M.; Tsongalis, Gregory J.; Caliendo, Angela M.; Olsen, Randall J.; Ashwood, Edward R.; Bale, Sherri; Benirschke, Robert; Carlow, Dean; Funke, Birgit H.; Grody, Wayne W.; Hayden, Randall T.; Hegde, Madhuri; Lyon, Elaine; Murata, Kazunori; Pessin, Melissa; Press, Richard D.; Thomson, Richard B.
Title: The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care
  • Document date: 2017_7_16
    • ID: jzwwses4_24
    Snippet: In the CAP KRAS-B-2015 mailing, 204 laboratories reported results from testing 3 blinded proficiency-testing specimens. The specimens contained recurring somatic mutations in KRAS exons 12 or 13 (NM_004985.3), c.35G>T (p.G12 V), and c.38G>A (p.G13D). An acceptable response was reported by over 96% of the laboratories for both mutations (197/204 for p.G12V and 195/202 for p.G13D). The vast majority of reporting laboratories utilized LDPs. 57 KRAS .....
    Document: In the CAP KRAS-B-2015 mailing, 204 laboratories reported results from testing 3 blinded proficiency-testing specimens. The specimens contained recurring somatic mutations in KRAS exons 12 or 13 (NM_004985.3), c.35G>T (p.G12 V), and c.38G>A (p.G13D). An acceptable response was reported by over 96% of the laboratories for both mutations (197/204 for p.G12V and 195/202 for p.G13D). The vast majority of reporting laboratories utilized LDPs. 57 KRAS and RAS family gene mutation analysis is also critical in the management of patients with non-small-cell lung cancer (NSCLC) and other tumors, 58 for which FDA approval of kits has not occurred; LDPs or off-label use of kits is required.

    Search related documents:
    Co phrase search for related documents
    • FDA approval and kit FDA approval: 1, 2
    • FDA approval and lung cancer: 1, 2, 3, 4
    • FDA approval and non small cell: 1
    • FDA approval and non small cell lung cancer: 1
    • FDA approval and NSCLC non small cell lung cancer: 1
    • FDA approval and proficiency test: 1
    • FDA approval and vast majority: 1, 2
    • gene mutation and lung cancer: 1, 2, 3, 4
    • gene mutation and non small cell: 1
    • gene mutation and non small cell lung cancer: 1
    • gene mutation and NSCLC non small cell lung cancer: 1
    • gene mutation and somatic mutation: 1, 2, 3